Electrochemical Studies of the Effects of Substance P on Dopamine Terminals in the Rat Striatum

Tang, Feng‐Yao; Chiu, Te-Fa; Wang, Yun

doi:10.1006/exnr.1998.6834

Cited by 18 publications

(7 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has a critical role in the regulation of affective behavior, neurochemical responses to stress [70] and regulation of excitability of dorsal horn nociceptive neurons [71]. SP has been reported to elicit interluekin-1 (IL-1) production in macrophages [72,73], known to sensitize neutrophils [74] and enhance dopamine release in the substantia nigra region in cat brain [75,76]. It is known to secrete catecholamines and play a role in regulation of blood pressure and hypertension [77,78].…”

Section: Physiological Responses Of Spmentioning

confidence: 99%

Substance P: Structure, Function, and Therapeutics

Datar

Srivastava²,

Coutinho³

et al. 2004

CTMC

148

View full text Add to dashboard Cite

Extensive efforts since 1931, on the structural determination of the mammalian tachykinin SP by NMR, CD and IR have turned out to be inconclusive. Studies are now being concentrated on the structural properties and characteristics of various NK receptors (NK(1), NK(2) and NK(3)) with the help of genetics, cloning, receptor engineering, mutagenesis and modeling. This knowledge is now being fruitfully used in the development of non-peptide NK(1) receptor antagonists that essentially block the pharmacological effects of SP. It is now being realized that the simultaneous blockade of two or more receptors gives promising results in emesis, depression and pulmonary obstructive diseases. In addition to the synthetic compounds, the discovery of antagonists from natural origin has added a great value to this field. In this review we have made an attempt to present the structural characteristics of SP, its analogs and antagonists, the structural characteristics of the NK receptor, and structure activity relationships that have helped to improve the therapeutic utilities of SP antagonists.

show abstract

Section: Physiological Responses Of Spmentioning

confidence: 99%

Substance P: Structure, Function, and Therapeutics

Datar

Srivastava²,

Coutinho³

et al. 2004

CTMC

148

View full text Add to dashboard Cite

show abstract

“…This type of interaction between SP and central dopaminergic systems is proposed to play an important role in mediating behavior under basal ganglia dopamine regulation (James and Starr 1979; Kelley and Iversen 1979). In addition, because the injection of this tachykinin into the VTA (Cador et al 1989; Kelley et al 1989; Kelley and Delfs 1991; West and Michael 1991), frontal cortex (Krasnova et al 2000), nucleus accumbens (Kalivas and Miller 1984; Nikolaev et al 2004), striatum (Tang et al 1998; Preston et al 2000; Krasnova et al 2000), or substantia nigra (Tan and Tsou 1988a,b) increases neuronal firing and dopamine turnover, it is not surprising that drugs which alter dopamine activity associated with these systems would also influence associated SP pathways. In fact, previous studies demonstrated that changes in activity of the dopaminergic pathways induced by amphetamines (Ritter et al 1984, 1985; Sonsalla et al 1984, 1986; Hanson et al 1986a,b, 2002; Bannon et al 1987; Ujike et al 1988) or cocaine (Alburges et al 2000; Kraft et al 2001) significantly alter SP systems in limbic and basal ganglia regions.…”

Section: Introductionmentioning

confidence: 99%

Responses of limbic and extrapyramidal substance P systems to nicotine treatment

et al. 2008

View full text Add to dashboard Cite

Rationale-Neuropeptides are linked to the psychopathology of stimulants of abuse, principally through dopamine mechanisms. Substance P (SP) is one of these neuropeptides and is associated with both limbic and extrapyramidal dopaminergic pathways and likely contributes to the pharmacology of these stimulants. The effects of nicotine on these dopamine systems has also been extensively studied, however, its effects on the associated SP pathways, have received little attention.Objectives-In the present study, we elucidated the effects of nicotine treatment on limbic and extrapyramidal SP systems by measuring changes in associated SP tissue concentrations. Results-The nicotine treatment significantly but temporarily decreased substance P-like immunoreactivity (SPLI) content in the ventral tegmental area (VTA) and substantia nigra 12-18 h after drug exposure. The nicotine-mediated changes in SPLI were selectively blocked by pretreatment with mecamylamine as well as a dopamine D 1 , D 2 , or both receptor antagonists. Other brain areas that also selectively demonstrated nicotine-related declines in SPLI content included prefrontal cortex, the nucleus accumbens shell and the very posterior caudate. Materials and methods-MaleConclusions-These findings indicate that some limbic and basal ganglia SP systems are significantly affected by exposure to nicotine through processes mediated by nicotinic and dopaminergic receptors, suggesting a role for SP pathways in nicotine's limbic and extrapyramidal effects.

show abstract

“…Specifically, application of NT (Chapman et al, 1992) or SP (Tang et al, 1998) are reported to be excitatory, while DYN and MENK are reported to be inhibitory on striatal dopaminergic activity (Steiner and Gerfen, 1998). Consequently, there are actions both by drugs of abuse and these neuropeptide systems on DA pathways (Ervin et al, 1981;Steiner and Gerfen, 1998).…”

Section: Introductionmentioning

confidence: 99%

Brain levels of neuropeptides in human chronic methamphetamine users

et al. 2007

View full text Add to dashboard Cite

SummaryAnimal data show that neuropeptide systems in the dopamine-rich brain areas of the striatum (caudate, putamen, and nucleus accumbens) are influenced by exposure to psychostimulants, suggesting that neuropeptides are involved in mediating aspects of behavioral responses to drugs of abuse. To establish in an exploratory study whether levels of neuropeptides are altered in brain of human methamphetamine users, we measured tissue concentrations of dynorphin, metenkephalin, neuropeptide Y, neurotensin, and substance P in autopsied brains of 16 chronic methamphetamine users and 17 matched control subjects. As expected, levels of most neuropeptides were enriched in dopamine-linked brain regions such as the nucleus accumbens and striatum of normal human brain. In contrast to animal findings of increased neuropeptide levels following short-term methamphetamine exposure, striatal neuropeptide concentrations were either normal or moderately decreased in the methamphetamine users. In other examined dopamine-poor cortical and subcortical brain areas, neuropeptide levels were generally either normal or variably reduced. Although the neuropeptide differences might be explained by methamphetamine-induced damage to neuropeptidecontaining neurons, our human data are consistent with the possibility that, at least in the human striatum, long-term methamphetamine exposure leads to an adaptive process that is distinct from that which increases neuropeptide levels after acute methamphetamine exposure.

show abstract

Electrochemical Studies of the Effects of Substance P on Dopamine Terminals in the Rat Striatum

Cited by 18 publications

References 49 publications

Substance P: Structure, Function, and Therapeutics

Substance P: Structure, Function, and Therapeutics

Responses of limbic and extrapyramidal substance P systems to nicotine treatment

Brain levels of neuropeptides in human chronic methamphetamine users

Contact Info

Product

Resources

About